Table 2

Baseline disease activities in TNF-low, TNF-int and TNF-high patients

Baseline-TNF
TNF-low (n=94)TNF-int (n=191)TNF-high (n=42)p Value (overall)
DAS28-CRP5.3 (4.9, 5.9)5.5 (5.0, 6.2)5.9 (5.2, 6.7)0.002
DAS28-ESR5.9 (5.5, 6.4)6.2 (5.7, 6.8)6.8 (6.2, 7.3)<0.001
TJC, 68 joints14.0 (10.0, 21.0)15.0 (11.0, 23.0)16.5 (12.0, 23.0)0.153
SJC, 66 joints11.0 (8.0, 16.0)13.0 (9.0, 17.0)12.5 (10.0, 18.0)0.041
Patient pain VAS, mm49.0 (37.0, 65.0)58.0 (40.0, 72.0)68.5 (46.0, 88.0)<0.001
Patient global VAS, mm51.0 (36.0, 64.0)56.0 (36.0, 72.0)65.0 (43.0, 86.0)0.016
Physician global VAS, mm62.0 (50.0, 75.0)65.0 (49.0, 77.0)72.0 (51.0, 82.0)0.081
CRP (mg/dl)2.0 (1.0, 3.9)2.4 (1.2, 3.9)2.8 (1.4, 5.8)0.028
ESR (mm/h)46.0 (33.0, 65.0)53.0 (35.0, 72.0)67.5 (40.0, 89.0)0.001
HAQ1.0 (0.5, 1.4)1.1 (0.9, 1.6)1.4 (1.0, 2.1)0.002
TSS37.0 (10.5, 76.0)*36.0 (12.5, 72.3)22.5 (13.0, 56.0)0.960
Estimated yearly progression of TSS, point/year5.8 (2.8, 12.0)*6.3 (3.4, 11.3)5.5 (2.5, 10.0)0.833
RF value, IU/ml85 (27, 215)81 (37, 167)238 (126, 554)0.007
Anti-CCP antibodies value, IU/ml91 (17, ≥100)≥100 (30, ≥100)≥100 (≥100, ≥100)0.012
MMP-3 value, ng/ml205 (105, 377)216 (102, 391)268 (114, 640)0.214
  • Data in baseline value are median (IQR).

  • Baseline disease activities were evaluated in the patients enrolled in the RISING study (n=327). The associations of baseline-tumour necrosis factor alpha (TNF) with baseline disease activities were analysed in the three groups (TNF-low, TNF-int and TNF-high patients) employing the Kendall rank correlation coefficient.

  • * n=93.

  • n=190.

  • CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MMP-3, matrix metalloproteinase 3; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TSS, total modified Sharp score; VAS, visual analogue scale.